Cargando…
Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge
BACKGROUND: Guidelines recommend using multiple drugs in patients with heart failure (HF) with reduced ejection fraction, but there is a paucity of real‐world data on the simultaneous initiation of the 4 pharmacological pillars at discharge after a decompensation event. METHODS AND RESULTS: A retros...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356099/ https://www.ncbi.nlm.nih.gov/pubmed/37382176 http://dx.doi.org/10.1161/JAHA.122.029071 |
_version_ | 1785075198261723136 |
---|---|
author | D'Amario, Domenico Rodolico, Daniele Delvinioti, Agni Laborante, Renzo Iacomini, Chiara Masciocchi, Carlotta Restivo, Attilio Ciliberti, Giuseppe Galli, Mattia Paglianiti, Antonio Donato Iaconelli, Antonio Zito, Andrea Lenkowicz, Jacopo Patarnello, Stefano Cesario, Alfredo Valentini, Vincenzo Crea, Filippo |
author_facet | D'Amario, Domenico Rodolico, Daniele Delvinioti, Agni Laborante, Renzo Iacomini, Chiara Masciocchi, Carlotta Restivo, Attilio Ciliberti, Giuseppe Galli, Mattia Paglianiti, Antonio Donato Iaconelli, Antonio Zito, Andrea Lenkowicz, Jacopo Patarnello, Stefano Cesario, Alfredo Valentini, Vincenzo Crea, Filippo |
author_sort | D'Amario, Domenico |
collection | PubMed |
description | BACKGROUND: Guidelines recommend using multiple drugs in patients with heart failure (HF) with reduced ejection fraction, but there is a paucity of real‐world data on the simultaneous initiation of the 4 pharmacological pillars at discharge after a decompensation event. METHODS AND RESULTS: A retrospective data mart, including patients diagnosed with HF, was implemented. Consecutively admitted patients with HF with reduced ejection fraction were selected through an automated approach and categorized according to the number/type of treatments prescribed at discharge. The prevalence of contraindications and cautions for HF with reduced ejection fraction treatments was systematically assessed. Logistic regression models were fitted to assess predictors of the number of treatments (≥2 versus <2 drugs) prescribed and the risk of rehospitalization. A population of 305 patients with a first episode of HF hospitalization and a diagnosis of HF with reduced ejection fraction (ejection fraction, <40%) was selected. At discharge, 49.2% received 2 current recommended drugs, β‐blockers were prescribed in 93.4%, while a renin‐angiotensin system inhibitor or an angiotensin receptor–neprilysin inhibitor was prescribed in 68.2%. A mineralocorticoid receptor antagonist was prescribed in 32.5%, although none of the patients showed contraindications to mineralocorticoid receptor antagonist prescription. A sodium‐glucose cotransporter 2 inhibitor could be prescribed in 71.1% of patients. On the basis of current recommendations, 46.2% could receive the 4 foundational drugs at discharge. Renal dysfunction was associated with <2 foundational drugs prescribed. After adjusting for age and renal function, use of ≥2 drugs was associated with lower risk of rehospitalization during the 30 days after discharge. CONCLUSIONS: A quadruple therapy could be directly implementable at discharge, potentially providing prognostic advantages. Renal dysfunction was the main prevalent condition limiting this approach. |
format | Online Article Text |
id | pubmed-10356099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103560992023-07-20 Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge D'Amario, Domenico Rodolico, Daniele Delvinioti, Agni Laborante, Renzo Iacomini, Chiara Masciocchi, Carlotta Restivo, Attilio Ciliberti, Giuseppe Galli, Mattia Paglianiti, Antonio Donato Iaconelli, Antonio Zito, Andrea Lenkowicz, Jacopo Patarnello, Stefano Cesario, Alfredo Valentini, Vincenzo Crea, Filippo J Am Heart Assoc Original Research BACKGROUND: Guidelines recommend using multiple drugs in patients with heart failure (HF) with reduced ejection fraction, but there is a paucity of real‐world data on the simultaneous initiation of the 4 pharmacological pillars at discharge after a decompensation event. METHODS AND RESULTS: A retrospective data mart, including patients diagnosed with HF, was implemented. Consecutively admitted patients with HF with reduced ejection fraction were selected through an automated approach and categorized according to the number/type of treatments prescribed at discharge. The prevalence of contraindications and cautions for HF with reduced ejection fraction treatments was systematically assessed. Logistic regression models were fitted to assess predictors of the number of treatments (≥2 versus <2 drugs) prescribed and the risk of rehospitalization. A population of 305 patients with a first episode of HF hospitalization and a diagnosis of HF with reduced ejection fraction (ejection fraction, <40%) was selected. At discharge, 49.2% received 2 current recommended drugs, β‐blockers were prescribed in 93.4%, while a renin‐angiotensin system inhibitor or an angiotensin receptor–neprilysin inhibitor was prescribed in 68.2%. A mineralocorticoid receptor antagonist was prescribed in 32.5%, although none of the patients showed contraindications to mineralocorticoid receptor antagonist prescription. A sodium‐glucose cotransporter 2 inhibitor could be prescribed in 71.1% of patients. On the basis of current recommendations, 46.2% could receive the 4 foundational drugs at discharge. Renal dysfunction was associated with <2 foundational drugs prescribed. After adjusting for age and renal function, use of ≥2 drugs was associated with lower risk of rehospitalization during the 30 days after discharge. CONCLUSIONS: A quadruple therapy could be directly implementable at discharge, potentially providing prognostic advantages. Renal dysfunction was the main prevalent condition limiting this approach. John Wiley and Sons Inc. 2023-06-29 /pmc/articles/PMC10356099/ /pubmed/37382176 http://dx.doi.org/10.1161/JAHA.122.029071 Text en © 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Research D'Amario, Domenico Rodolico, Daniele Delvinioti, Agni Laborante, Renzo Iacomini, Chiara Masciocchi, Carlotta Restivo, Attilio Ciliberti, Giuseppe Galli, Mattia Paglianiti, Antonio Donato Iaconelli, Antonio Zito, Andrea Lenkowicz, Jacopo Patarnello, Stefano Cesario, Alfredo Valentini, Vincenzo Crea, Filippo Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge |
title | Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge |
title_full | Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge |
title_fullStr | Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge |
title_full_unstemmed | Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge |
title_short | Eligibility for the 4 Pharmacological Pillars in Heart Failure With Reduced Ejection Fraction at Discharge |
title_sort | eligibility for the 4 pharmacological pillars in heart failure with reduced ejection fraction at discharge |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356099/ https://www.ncbi.nlm.nih.gov/pubmed/37382176 http://dx.doi.org/10.1161/JAHA.122.029071 |
work_keys_str_mv | AT damariodomenico eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT rodolicodaniele eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT delviniotiagni eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT laboranterenzo eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT iacominichiara eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT masciocchicarlotta eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT restivoattilio eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT cilibertigiuseppe eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT gallimattia eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT paglianitiantoniodonato eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT iaconelliantonio eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT zitoandrea eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT lenkowiczjacopo eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT patarnellostefano eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT cesarioalfredo eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT valentinivincenzo eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge AT creafilippo eligibilityforthe4pharmacologicalpillarsinheartfailurewithreducedejectionfractionatdischarge |